Effets osseux des stéroides inhalés. [Inhaled steroids effect on bones]

Détails

ID Serval
serval:BIB_C2BBAC933F19
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Effets osseux des stéroides inhalés. [Inhaled steroids effect on bones]
Périodique
Revue Médicale de la Suisse Romande
Auteur(s)
Weilenmann  C., Lamy  O., Fellrath  J. M., Spertini  F.
ISSN
0035-3655 (Print)
Statut éditorial
Publié
Date de publication
03/1999
Volume
119
Numéro
3
Pages
241-8
Notes
English Abstract Journal Article Review --- Old month value: Mar
Résumé
Inhaled corticosteroids (ICS) are the mainstay of asthma treatment, when an antiinflammatory agent is warranted. The development of the ICS has permitted to diminish the adverse effects associated with oral steroids and with equipotent doses there are less adverse effects with ICS on bone metabolism compared to oral steroids. There is now reassuring evidence that doses of < or = 400 micrograms for children and < or = 1000 micrograms for adults are safe and do not appear to have clinically significant adverse effect on bone density or bone growth. When exceeding the recommended thresholds for more than 3 months, osteoporosis prevention would be appropriate. Furthermore a mineral bone density measurement might be done in this context in order to identify those persons who are at risk of developing or worsening preexisting osteoporosis. Growth monitoring is justified in any child taking ICS. Biochemical markers of bone formation and resorption might give complementary information to the mineral bone density measurement. The addition of a leukotriene receptor antagonist and or of a chromone may allow a reduction in the requirement for ICS in mild to moderate asthma. Finally the achievement of an increased glucocorticoid potency combined with an improved airway selectivity and a shorter plasmatic half-life of the ICS will further contribute to diminish their effects on bone metabolism.
Mots-clé
Administration, Inhalation Adrenal Cortex Hormones/administration & dosage/pharmacokinetics/*pharmacology Adult Anti-Inflammatory Agents/administration & dosage/pharmacokinetics/*pharmacology Asthma/*drug therapy Bone Development/*drug effects Bone Diseases, Metabolic/chemically induced/prevention & control Bone and Bones/*drug effects/metabolism Child Drug Monitoring Humans Steroids
Pubmed
Création de la notice
25/01/2008 14:55
Dernière modification de la notice
03/03/2018 21:10
Données d'usage